Bayesian Statistics in Oncology A Guide for the Clinical Investigator

被引:37
作者
Adamina, Michel [1 ,2 ]
Tomlinson, George [3 ]
Guller, Ulrich [4 ,5 ]
机构
[1] Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada
[2] Univ Basel, Dept Surg, Basel, Switzerland
[3] Univ Toronto, Dept Med, Univ Hosp Network, Toronto, ON, Canada
[4] Univ Toronto, Dept Surg, Toronto, ON, Canada
[5] Univ Bern, Dept Surg, Bern, Switzerland
关键词
Bayesian analysis; biostatistics; clinical trial; oncology; ACCELERATED RADIOTHERAPY CHART; RANDOMIZED PHASE-II; CELL LUNG-CANCER; CONVENTIONAL RADIOTHERAPY; DOSE-ESCALATION; TRIALS; COMBINATION; THERAPY; DESIGN; TIME;
D O I
10.1002/cncr.24628
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The rise of evidence-based medicine as well as important progress in statistical methods and computational power have led to a second birth of the >200-year-old Bayesian framework. The use of Bayesian techniques, in particular in the design and interpretation of clinical trials, offers several substantial advantages over the classical statistical approach. First, in contrast to classical statistics, Bayesian analysis allows a direct statement regarding the probability that a treatment was beneficial. Second, Bayesian statistics allow the researcher to incorporate any prior information in the analysis of the experimental results. Third, Bayesian methods can efficiently handle complex statistical models, which are suited for advanced clinical trial designs. Finally, Bayesian statistics encourage a thorough consideration and presentation of the assumptions underlying an analysis, which enables the reader to fully appraise the authors' conclusions. Both Bayesian and classical statistics have their respective strengths and limitations and should be viewed as being complementary to each other; we do not attempt to make a head-to-head comparison, as this is beyond the scope of the present review. Rather, the objective of the present article is to provide a nonmathematical, reader-friendly overview of the current practice of Bayesian statistics coupled with numerous intuitive examples from the field of oncology. It is hoped that this educational review will be a useful resource to the oncologist and result in a better understanding of the scope, strengths, and limitations of the Bayesian approach. Cancer 2009;115:5371-81. (C) 2009 American Cancer Society.
引用
收藏
页码:5371 / 5381
页数:11
相关论文
共 54 条
[1]  
Ashby D, 2000, STAT MED, V19, P3291, DOI 10.1002/1097-0258(20001215)19:23<3291::AID-SIM627>3.0.CO
[2]  
2-T
[3]   Bayeswatch: an overview of Bayesian statistics [J].
Austin, PC ;
Brunner, LJ ;
Hux, JE .
JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2002, 8 (02) :277-286
[4]  
*BASIS GROUP, BASIS BAYES STAND SC
[5]  
Bayes T., 1763, Philos. Trans. R. Soc. Lond., V53, P370
[6]   Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis [J].
Berry, DA .
CLINICAL TRIALS, 2005, 2 (04) :295-300
[7]   Effect of screening and adjuvant therapy on mortality from breast cancer [J].
Berry, DA ;
Cronin, KA ;
Plevritis, SK ;
Fryback, DG ;
Clarke, L ;
Zelen, M ;
Mandelblatt, JS ;
Yakovlev, AY ;
Habbema, JDF ;
Feuer, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (17) :1784-1792
[9]   Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].
Buzdar, AU ;
Ibrahim, NK ;
Francis, D ;
Booser, DJ ;
Thomas, ES ;
Theriault, RL ;
Pusztai, L ;
Green, MC ;
Arun, BK ;
Giordano, SH ;
Cristofanilli, M ;
Frye, DK ;
Smith, TL ;
Hunt, KK ;
Singletary, SE ;
Sahin, AA ;
Ewer, MS ;
Buchholz, TA ;
Berry, D ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685
[10]  
Chaloner K, 2001, STAT MED, V20, P581, DOI 10.1002/sim.694